Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AIMD

Ainos Inc

Dec 10 • 04:00PM ET

0.4440

Dollar change +0.0115
Percentage change 2.66	%

Healthcare • Medical Devices • USA • NASD

Peers: MRNA GILD INVA CDMO RGEN ALT URGN VTGN ACHV

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.66	Insider Own	70.19%	Shs Outstand	13.81M	Perf Week	1.44%
Market Cap	6.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.13M	Perf Month	-7.46%
Income	-16.13M	PEG	-	EPS next Q	-	Inst Own	1.33%	Short Float	3.92%	Perf Quarter	-14.62%
Sales	0.04M	P/S	153.50	EPS this Y	-	Inst Trans	115.70%	Short Ratio	0.44	Perf Half Y	-48.37%
Book/sh	1.30	P/B	0.34	EPS next Y	-	ROA	-49.47%	Short Interest	0.16M	Perf Year	-84.92%
Cash/sh	0.37	P/C	1.19	EPS next 5Y	-	ROE	-70.60%	52W Range	0.40 - 4.29	Perf YTD	-78.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.59%	ROI	-59.71%	52W High	-89.65%	Beta	1.43
Dividend TTM	-	Quick Ratio	1.33	Sales past 5Y	768.29%	Gross Margin	-352.79%	52W Low	11.00%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.37	EPS Y/Y TTM	-7.05%	Oper. Margin	-35985.46%	RSI (14)	45.63	Volatility	5.45% 8.45%
Employees	46	Debt/Eq	0.68	Sales Y/Y TTM	-96.44%	Profit Margin	-39705.78%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.50	EPS Q/Q	55.26%	Payout	-	Rel Volume	0.20	Prev Close	0.43
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	369.07K	Price	0.44
SMA20	-1.38%	SMA50	-8.25%	SMA200	-43.34%	Trades		Volume	85,675	Change	2.66%

Dec-04-24 08:00AM	Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing (ACCESSWIRE)
Dec-02-24 08:00AM	Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sj gren's Syndrome Drug (Newsfile) -8.28%
Nov-13-24 08:00AM	Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments (ACCESSWIRE)
Nov-11-24 08:00AM	Ainos Announces IRB Approval for Sjögrens Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 (ACCESSWIRE)
08:00AM	Ainos Announces IRB Approval for Sjogren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 (ACCESSWIRE)
08:00AM	Loading…
Nov-08-24 08:00AM	Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities (ACCESSWIRE)
Nov-06-24 04:30PM	Ainos Reports Third Quarter 2024 Financial Results (ACCESSWIRE) +14.67% -5.33%
Oct-28-24 08:00AM	Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets (ACCESSWIRE)
Oct-24-24 10:50AM	Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast (ACCESSWIRE)
Oct-07-24 08:00AM	Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies (ACCESSWIRE)
Sep-25-24 08:00AM	Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA (ACCESSWIRE) +18.26%
Sep-24-24 10:55AM	Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome (ACCESSWIRE)
Sep-23-24 08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options (ACCESSWIRE)
08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjogren's Syndrome, a Rare Disease With Limited Treatment Options (ACCESSWIRE)
Sep-20-24 08:00AM	Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts (ACCESSWIRE) -5.68%
08:00AM	Loading…
Sep-17-24 08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA (ACCESSWIRE)
Sep-03-24 08:30AM	Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention (ACCESSWIRE)
Aug-27-24 08:30AM	Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Aug-26-24 08:30AM	Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter (ACCESSWIRE) +6.09%
Aug-19-24 09:15AM	Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety (GlobeNewswire)
Aug-12-24 08:00AM	Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 (ACCESSWIRE) +8.06%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-09-24 04:15PM	Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing (ACCESSWIRE)
Aug-06-24 07:30AM	Ainos Concludes Growth Financing From Lind Partners (ACCESSWIRE) -6.49%
Aug-05-24 04:15PM	Ainos Reports Second Quarter 2024 Financial Results (ACCESSWIRE) -17.06%
Jul-23-24 08:30AM	Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug (ACCESSWIRE)
Jun-14-24 08:00AM	Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA (ACCESSWIRE) +7.29%
May-15-24 08:00AM	Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market (ACCESSWIRE)
May-13-24 09:54PM	AIMD Stock Earnings: Ainos Reported Results for Q1 2024 (InvestorPlace)
04:10PM	Ainos Reports First Quarter 2024 Financial Results (ACCESSWIRE)
08:00AM	Loading…
May-07-24 08:00AM	Ainos Raises $9 Million in Growth Capital with Existing Shareholder (ACCESSWIRE)
Mar-08-24 04:20PM	Ainos Reports Full Year 2023 Financial Results (ACCESSWIRE) +83.04% -20.00%
07:58AM	Why Is Ainos (AIMD) Stock Up 153% Today? (InvestorPlace)
Mar-04-24 08:22AM	Why Is Ainos (AIMD) Stock Up 57% Today? (InvestorPlace) +35.24%
Feb-08-24 08:35AM	Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing (GlobeNewswire)
Feb-06-24 09:51AM	Small-Cap Growth Virtual Investor Conference Agenda Announced for February 7th, 2024 (GlobeNewswire) -7.81%
Feb-05-24 09:00AM	Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms (ACCESSWIRE)
Feb-01-24 08:35AM	Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th (GlobeNewswire)
Jan-24-24 09:00AM	Ainos Announces $1.75 Million Follow-On Funding (ACCESSWIRE) -10.34%
Jan-05-24 08:08AM	Why Is Ainos (AIMD) Stock Up 157% Today? (InvestorPlace) +58.38%
Jan-02-24 09:00AM	Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) -6.34%
Dec-26-23 09:00AM	Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell (ACCESSWIRE)
Dec-14-23 05:52AM	AIMD Stock Earnings: Ainos Reported Results for Q1 2023 (InvestorPlace)
Dec-12-23 08:00AM	Ainos, Inc. Announces Stock Consolidation (ACCESSWIRE)
Nov-28-23 08:30AM	Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical (ACCESSWIRE)
Nov-21-23 08:30AM	Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA (ACCESSWIRE)
Nov-09-23 04:30PM	Ainos Reports Third Quarter 2023 Financial Results (ACCESSWIRE)
Nov-06-23 08:00AM	Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA (ACCESSWIRE)
Sep-25-23 08:30AM	Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement (ACCESSWIRE)
Sep-19-23 12:26PM	With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients (Newsfile)
Sep-18-23 07:00AM	Ainos VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) -21.30%
Sep-05-23 07:00AM	Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan (ACCESSWIRE)
Aug-15-23 01:29PM	Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond (Newsfile)
Aug-11-23 04:30PM	Ainos Reports Second Quarter 2023 Financial Results (ACCESSWIRE) +5.14%
Aug-10-23 08:00AM	Ainos Celebrates First Listing Anniversary on Nasdaq (ACCESSWIRE) -7.16%
Aug-09-23 08:00AM	Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption (ACCESSWIRE) -6.49%
Jun-27-23 08:30AM	Ainos Issues Mid-Year Business Update Letter to Shareholders (ACCESSWIRE)
Jun-20-23 08:30AM	Ainos Provides Insights Into Its AI Nose Technology (ACCESSWIRE) -7.97%
Jun-14-23 09:00AM	Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target (ACCESSWIRE)
Jun-07-23 09:00AM	Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target (ACCESSWIRE) +5.20%
May-30-23 09:00AM	Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales (ACCESSWIRE)
May-17-23 04:30PM	Ainos Appoints Amanda Sung as New Chief Financial Officer (ACCESSWIRE) -5.14%
May-12-23 04:15PM	Ainos Reports First Quarter 2023 Financial Results (ACCESSWIRE)
Mar-31-23 05:50PM	Ainos Reports Fourth Quarter and Full Year 2022 Financial Results (ACCESSWIRE)
Mar-21-23 07:00AM	Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan (ACCESSWIRE) -16.13%
Mar-14-23 07:00AM	Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) +79.17%
Mar-13-23 04:30PM	Ainos Announces US$3 Million Convertible Notes Private Placement (ACCESSWIRE) +5.88%
Jan-23-23 07:00AM	Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug (ACCESSWIRE) -7.42%
Jan-17-23 07:00AM	Ainos Issues 2023 Shareholder Letter (ACCESSWIRE)
Nov-21-22 05:30AM	Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals (PR Newswire) -15.75%
Nov-07-22 07:30AM	Ainos Reports Unaudited Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 07:00AM	Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation (PR Newswire)
Oct-31-22 07:00AM	Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization (ACCESSWIRE) -5.00%
Sep-30-22 07:00AM	Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron (ACCESSWIRE) +36.96%
Aug-24-22 07:00AM	Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms (ACCESSWIRE)
Aug-17-22 08:05AM	Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates (ACCESSWIRE)
Aug-15-22 07:20AM	Ainos Reports Second Quarter 2022 Financial Results (ACCESSWIRE) -9.75%
Aug-11-22 02:12PM	Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split (ACCESSWIRE) -15.12%
Aug-10-22 09:20AM	How Much Of Ainos, Inc. (NASDAQ:AIMD) Do Insiders Own? (Simply Wall St.) -11.48%
Aug-08-22 08:57PM	Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split (ACCESSWIRE) -66.11%
Jun-27-22 07:00AM	Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19 (PR Newswire)
Jun-21-22 07:00AM	Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan (ACCESSWIRE) -39.44%
Dec-07-21 06:55PM	Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection (ACCESSWIRE)
Nov-03-21 12:00PM	Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development (ACCESSWIRE)
Aug-16-21 09:23AM	Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives (ACCESSWIRE) -5.26%

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIMD

Ainos Inc

Upgrade your FINVIZ experience